Down syndrome and the genes of human chromosome 21: current knowledge and future potentials
Pritchard M.a · Reeves R.H.b · Dierssen M.c · Patterson D.d · Gardiner K.J.e
Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C., September 28–October 1, 2007
aMonash University, Victoria (Australia); bJohns Hopkins University School of Medicine, Baltimore, MD (USA) cCenter for Genomic Regulation, Barcelona (Spain); dEleanor Roosevelt Institute at the University of Denver eUniversity of Colorado Denver, Aurora, CO (USA)
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Down syndrome (DS), trisomy of human chromosome 21, is the most common genetic cause of intellectual disability. With an incidence in some countries as high as one in approximately 700 live births, and a complex, extensive and variably severe phenotype, Down syndrome is a significant medical and social challenge. In recent years, there has been a rapid increase in information on the functions of the genes of human chromosome 21, as well as in techniques and resources for their analysis. A recent workshop brought together experts on the molecular biology of Down syndrome and chromosome 21 with interested researchers in other fields to discuss advances and potentials for generating gene-phenotype correlations. An additional goal of the workshop was to work towards identification of targets for therapeutics that will correct features of DS. A knowledge-based approach to therapeutics also requires the correlation of chromosome 21 gene function with phenotypic features.
© 2008 S. Karger AG, Basel
- Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, et al: bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111–2115 (2004).
- Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, et al: Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 480:281–298 (2004).
- Besson V, Brault V, Duchon A, Togbe D, Bizot JC, et al: Modeling the monosomy for the telomeric part of human chromosome 21 reveals haploinsufficient genes modulating the inflammatory and airway responses. Hum Mol Genet 16:2040–2052 (2007).
- Best TK, Siarey RJ, Galdzicki Z: Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J Neurophysiol 97:892–900 (2007).
- Costa S, Zecca E, De Luca D, De Carolis MP, Romagnoli C: Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants. Eur J Obstet Gynecol Reprod Biol 131:154–157 (2007).
- Das M, Scappini E, Martin NP, Wong KA, Dunn S, et al: Regulation of neuron survival through an intersectin (ITSN)-phosphoinosite 3′-kinase C2(beta)-AKT pathway. Mol Cell Biol 27:7906–7917 (2007).
- Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, et al: Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 384:117–133 (1993).
Escorihuela RM, Fernandez-Teruel A, Vallina IF, Baamonde C, Lumbreras MA, et al: A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 99:143–146 (1995).
- Escorihuela RM, Vallina IF, Martinez-Cue C, Baamonde C, Dierssen M, et al: Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 247:171–114 (1998).
- Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, et al: Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10:411–413 (2007).
- Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, et al: Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93:13333–13338 (1996).
- Ligon KL, Fancy SP, Franklin RJ, Rowitch DH: Olig gene function in CNS development and disease. Glia 54:1–10 (2006).
- Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, et al: Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53:503–517 (2007).
- Lorenzi HA, Reeves RH: Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 1104:153–159 (2006).
- Mendoza-Naranjo A, Gonzalez-Billault C, Maccioni RB: Abeta1–42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. J Cell Sci 120:279–288 (2007).
- Moore CS: Postnatal lethality and cardiac anomalies in the Ts65Dn Down syndrome mouse model. Mamm Genome 17:1005–1012 (2006).
- Nishimura T, Yamaguchi T, Tokunaga A, Hara A, Hamaguchi T, et al: Role of numb in dendritic spine development with a Cdc42 GEF intersectin and EphB2. Mol Biol Cell 17:1273–1285 (2006).
- O’Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, et al: An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309:2033–2037 (2005).
- Olson LE, Roper RJ, Baxter LL, Carlson EJ, Epstein CJ, Reeves RH: Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev Dyn 230:581–589 (2004).
- Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, et al: A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177–184 (1995).
- Reeves RH, Garner CC: A year of unprecedented progress in Down syndrome basic research. Ment Retard Dev Disabil Res Rev 13:215–222 (2007).
- Richtsmeier JT, Baxter LL, Reeves RH: Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217:137–145 (2000).
- Scappini E, Koh TW, Martin NP, O’Bryan JP: Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum Mol Genet 16:1862–1871 (2007).
- Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, et al: Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 98:1266–1277 (2006).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.